In a filing, Arcadia Biosciences Inc. revealed its Chief Financial Officer Schaefer Thomas J. acquired Company’s shares for reported $2382.0 on Aug 04. In the deal valued at $3.67 per share,649 shares were bought. As a result of this transaction, Schaefer Thomas J. now holds 719 shares worth roughly $ 2847.24.
Then, Jacot Stanley Jr bought 5,000 shares, generating $21,550 in total proceeds. Upon buying the shares at $4.31, the Chief Executive Officer now owns 5,000 shares.
Before that, Schaefer Thomas J. bought 700 shares. Arcadia Biosciences Inc. shares valued at $161 were divested by the Chief Financial Officer at a price of $0.23 per share. As a result of the transaction, Schaefer Thomas J. now holds 2,800 shares, worth roughly $11088.0.
H.C. Wainwright reiterated its Arcadia Biosciences Inc. [RKDA] rating to a Buy in a research note published on Friday, August 17, 2020; the price target was $12. PT values the company’s stock at a premium of 67.0 to its Friday closing price.
Price Performance Review of RKDA
On Friday, Arcadia Biosciences Inc. [NASDAQ:RKDA] saw its stock jump 13.14% to $3.96. On the same session, the stock had its day’s lowest price of $3.57, but rose to a high of $4.79. Over the last five days, the stock has gained 10.00%. Arcadia Biosciences Inc. shares have fallen nearly -63.47% since the year began. Nevertheless, the stocks have fallen -88.65% over the past one year. While a 52-week high of $35.60 was reached on 03/02/23, a 52-week low of $3.15 was recorded on 06/23/23. SMA at 50 days reached $4.20, while 200 days put it at $7.88. A total of 0.21 million shares were traded, compared to the trading of 4700.0 shares in the previous session.
Levels Of Support And Resistance For RKDA Stock
The 24-hour chart illustrates a support level at 3.42, which if violated will result in even more drops to 2.89. On the upside, there is a resistance level at 4.64. A further resistance level may holdings at 5.33. The Relative Strength Index (RSI) on the 14-day chart is 49.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 62.41%. Stochastics %K at 14.35% indicates the stock is a buying.
How much short interest is there in Arcadia Biosciences Inc.?
A steep rise in short interest was recorded in Arcadia Biosciences Inc. stocks on Aug 14, 2023, dropping by 11980.0 shares to a total of 4660.0 shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 16640.0 shares. There was a decline of -257.08%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 0.42% of the overall stock float, the days-to-cover ratio (short ratio) fell to 0.09.
Arcadia Biosciences Inc. [RKDA] – Who Are The Largest Shareholders?
In filings from Sabby Management LLC, it is revealed that the company now owns 118,213 shares, or roughly 12.44% of the outstanding RKDA shares. In other words, the investor’s shares have risen by 65,339 from its previous 13-F filing of 52874.0.. Over the last quarter, Tower Research Capital LLC purchased 2,930 shares of Arcadia Biosciences Inc., while Morgan Stanley & Co. LLC bought 0 shares. At present, Group One Trading LP is holding 104 shares valued at $451.0. BlackRock Fund Advisors owned 38 shares of the company at the time of its most recent 13F filing, worth $165.0.
According to FactSet, Arcadia Biosciences Inc.’s share price will average $15.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 328.57 percent from its previous closing price of $3.50. Analysts expect Arcadia Biosciences Inc. stock to reach the higher price of $20.00, while the lowest price estimate is $10.00. However, 2 analysts have rated RKDA stock as a Buy in their predictions for 2023.